The Smart Investor
    Facebook Instagram
    Sunday, July 26
    Facebook Instagram LinkedIn
    The Smart Investor
    • Home
    • About
      • About Us
      • Careers
    • Smart Investing
      • Getting Started
      • Investing Strategy
      • Smart Analysis
      • Smart Reads
    • US Stocks
    • Special Free Reports!
    • As Featured on BT
    • Our Services
      • Our Services
      • Subscribe now!
    • Login
    • Cart
    The Smart Investor
    Home»Growth Stocks»4 US Stocks Reporting Impressive Growth That Can Power Your Portfolio Higher
    Growth Stocks

    4 US Stocks Reporting Impressive Growth That Can Power Your Portfolio Higher

    We identify four high-growth US stocks that can enable your investment portfolio to surge higher.
    Royston Y.By Royston Y.September 28, 2023Updated:October 4, 20235 Mins Read
    Facebook Twitter LinkedIn Email WhatsApp
    Dexcom G6 | Image credit: dexcom.com
    Dexcom G6 | Image credit: dexcom.com
    Share
    Facebook Twitter LinkedIn Email WhatsApp

    Investing can help you to grow your wealth and achieve your dream of a happy retirement.

    One method to work towards this goal is to park your money in dividend-paying stocks that generate a stream of passive income.

    Another is to allocate money to growth stocks that can improve their earnings and cash flow over time.

    As these businesses become more valuable, their share prices should also rise in tandem, yielding attractive capital gains.

    As time goes by, you can compound your wealth by reinvesting dividends from income stocks into promising growth stocks.

    This rinse-and-repeat cycle requires patience but is an effective way for you to grow your retirement nest egg.

    Here are four US stocks displaying solid growth that could push the value of your investment portfolio higher.

    ResMed (NYSE: RMD)

    ResMed manufactures and sells digital health technologies and cloud-connected medical devices to help patients with sleep apnea and COPD (chronic obstructive pulmonary disease).

    Its products are sold in more than 140 countries.

    The company just released its fiscal 2023 (FY2023) earnings for the year ending 30 June 2023.

    Revenue climbed 18% year on year to US$4.2 billion as its masks and patient interface businesses did well along with its residential software-as-a-service (SaaS) segment.

    Operating income improved by 13% year on year to US$1.1 billion while net profit jumped 15% year on year to US$897.6 million.

    In line with the good results, ResMed has increased its quarterly dividend by 9% year on year to US$0.48 per share.

    Operating cash flow nearly doubled year on year to US$693.3 million for FY2023 while free cash flow soared 165.2% year on year to US$573.6 million.

    During FY2023, the sleep apnea business acquired Somnoware, a company dealing with digital sleep and respiratory care software for sleep labs and physicians.

    Asana (NYSE: ASAN)

    Asana is a SaaS company that assists organisations to work smarter with a platform that helps teams share information and collaborate and also helps with capacity planning, product launches, and employee onboarding.

    The company boasts global companies such as Amazon (NASDAQ: AMZN), Accenture (NYSE: ACN), and Roche (SWX: ROG) as its customers.

    The software company reported a good set of earnings for its fiscal 2024 second quarter (2Q FY2024) ending 31 July 2023.

    Revenue rose 20.4% year on year to US$162.4 million with gross profit increasing by 20.7% year on year to US$146.2 million.

    Asana also generated a free cash flow of US$14.6 million for the quarter, reversing the negative free cash flow a year ago.

    The business has more than 139,000 paying customers in more than 200 countries and territories.

    Additionally, the number of customers spending US$100,000 or more jumped 20% year on year to 553.

    DexCom (NASDAQ: DXCM)

    DexCom is a healthcare company that manufactures and distributes continuous glucose monitoring (CGM) systems.

    The company aims to simplify and improve diabetes management around the world.

    For 2Q 2023, revenue improved by 25.2% year on year to US$871.3 million while operating income surged by 66.4% year on year to US$128.1 million.

    Net profit more than doubled year on year to US$115.9 million from US$50.9 million a year ago.

    The company’s free cash flow more than quadrupled year on year to US$212 million for 2Q 2023.

    During the quarter, DexCom commenced commercial production at its Malaysia manufacturing facility.

    The company sees a large total addressable market for its DexCom G6 CGM System as there are more than 25 million people in the US with Type 2 Diabetes who have not progressed to insulin therapy.

    DexCom will tap on its digital health partnerships and pursue reimbursed access (through insurance tie-ups) to catalyse its growth.

    Rollins (NYSE: ROL)

    Rollins is a commercial services company that provides pest control services and protection against termites, rodents, and insects.

    The company has more than 19,000 employees from more than 800 locations.

    For 2Q 2023, Rollins reported a 14.9% year on year increase in revenue to US$820.7 million.

    Operating income increased by the same percentage quantum to US$154.8 million while net profit improved by 8.4% year on year to US$110.1 million.

    The business also generated a positive free cash flow of US$140.6 million, up 17.8% from the prior year.

    Rollins also declared a quarterly dividend of US$0.13 per share, up an impressive 30% year on year from 2Q 2022.

    Back in April, the company completed the acquisition of Fox Pest Control, which provides services to residential customers across 13 states in the US.

    The acquired company is the 13th largest pest management company in America.

    This transaction is expected to add to earnings in the first full year of ownership and will be financed by cash and existing credit facilities.

    If you’re wondering about how you can leverage AI in your investment portfolio, and how it can boost your portfolio, good news! We just released an urgent Special Free Report to cover everything you need to know about AI and its implications for investors. Find out which listed companies are actively using AI to power their businesses and what you should do to prepare for the AI boom. Click here to download your free report now.

    Disclosure: Royston Yang does not own shares in any of the companies mentioned.

    Yahoo
    Share. Facebook Twitter LinkedIn Email WhatsApp

    Related Posts

    The Smart Investor Smart Reads Pic 8

    Smart Reads of the Week: Passive Income, Singapore Dividend Stocks, and REIT Growth Opportunities

    July 26, 2026

    Top Stock Market Highlights of the Week: Metro Holdings, Singapore Exchange, Mi Technovation and Singapore’s Inflation

    July 25, 2026
    bull market, stock market up

    Get Smart: The Biggest Risk When The STI is at a Record High

    July 24, 2026
    Facebook Instagram LinkedIn Telegram
    • Careers
    • Disclaimer & Privacy Policy
    • Advertising & Media Enquiries
    • Subscription Terms of Service
    © 2026 The Smart Investor. All Rights Reserved. The Smart Investor, thesmartinvestor.com.sg, an investment education website managed by The Investing Hustle Pte Ltd (Company Reg No. 201933459Z) is not licensed or otherwise regulated by the Monetary Authority of Singapore, and in particular, is not licensed or regulated to carry on business in providing any financial advisory service. Accordingly, any information provided on this site is meant purely for informational and investor educational purposes and should not be relied upon as financial advice. No information is presented with the intention to induce any reader to buy, sell, or hold a particular investment product or class of investment products. Rather, the information is presented for the purpose and intentions of educating readers on matters relating to financial literacy and investor education. Accordingly, any statement of opinion on this site is wholly generic and not tailored to take into account the personal needs and unique circumstances of any reader. The Smart Investor does not recommend any particular course of action in relation to any investment product or class of investment products. Readers are encouraged to exercise their own judgment and have regard to their own personal needs and circumstances before making any investment decision, and not rely on any statement of opinion that may be found on this site.

    Type above and press Enter to search. Press Esc to cancel.